Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

Grebely J, Matthews GV, Lloyd AR, Dore GJ.

Clin Infect Dis. 2013 Oct;57(7):1014-20. doi: 10.1093/cid/cit377. Epub 2013 May 31.

PMID:
23728143
2.

Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.

Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK.

Curr Opin Infect Dis. 2015 Dec;28(6):576-82. doi: 10.1097/QCO.0000000000000216. Review.

3.

Can hepatitis C virus infection be eradicated in people who inject drugs?

Grebely J, Dore GJ.

Antiviral Res. 2014 Apr;104:62-72. doi: 10.1016/j.antiviral.2014.01.002. Epub 2014 Jan 24. Review.

PMID:
24468275
4.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37. doi: 10.1093/cid/cit302.

PMID:
23884061
5.

Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.

Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L.

J Viral Hepat. 2014 Mar;21(3):198-207. doi: 10.1111/jvh.12129. Epub 2013 Jul 1.

PMID:
24438681
6.

Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.

Bruggmann P, Grebely J.

Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6. doi: 10.1016/j.drugpo.2014.08.014. Epub 2014 Aug 30.

7.

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Seeff LB, Hoofnagle JH.

Clin Liver Dis. 2003 Feb;7(1):261-87. Review.

PMID:
12691470
8.

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.

Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M.

Hepatology. 2013 Nov;58(5):1598-609. doi: 10.1002/hep.26431. Epub 2013 Aug 26.

9.

Hepatitis C transmission and treatment as prevention - The role of the injecting network.

Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, Thompson A, Doyle J, Pattison P, Robins G.

Int J Drug Policy. 2015 Oct;26(10):958-62. doi: 10.1016/j.drugpo.2015.05.006. Epub 2015 May 21.

PMID:
26072105
10.

The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention.

Martin NK, Vickerman P, Dore GJ, Hickman M.

Curr Opin HIV AIDS. 2015 Sep;10(5):374-80. doi: 10.1097/COH.0000000000000179. Review.

11.

HIV and HCV among people who inject drugs in Central Asia.

Walsh N, Maher L.

Drug Alcohol Depend. 2013 Nov;132 Suppl 1:S37-40. doi: 10.1016/j.drugalcdep.2013.06.030. Epub 2013 Jul 29.

PMID:
23906997
12.

HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.

Walsh N, Maher L.

Curr Opin HIV AIDS. 2012 Jul;7(4):339-44. doi: 10.1097/COH.0b013e328354131e. Review.

PMID:
22498482
13.

Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.

Matheï C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaeys G.

Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):227-32.

PMID:
27382943
14.

The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.

Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J.

BMC Infect Dis. 2017 Feb 21;17(1):162. doi: 10.1186/s12879-017-2256-5.

15.

The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?

Harris M, Albers E, Swan T.

Int J Drug Policy. 2015 Oct;26(10):963-9. doi: 10.1016/j.drugpo.2015.05.005. Epub 2015 Jun 4.

PMID:
26143385
16.

Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y.

Hepatology. 2016 Apr;63(4):1090-101. doi: 10.1002/hep.28227. Epub 2015 Dec 18.

PMID:
26390137
17.

Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.

Leask JD, Dillon JF.

Aliment Pharmacol Ther. 2016 Jul;44(2):145-56. doi: 10.1111/apt.13673. Epub 2016 May 20. Review.

PMID:
27199103
18.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users.

Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.

PMID:
26282715
19.

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M.

J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7.

20.

Enhancing the detection and management of acute hepatitis C virus infection.

Martinello M, Matthews GV.

Int J Drug Policy. 2015 Oct;26(10):899-910. doi: 10.1016/j.drugpo.2015.07.003. Epub 2015 Jul 16. Review.

PMID:
26254495

Supplemental Content

Support Center